^(153)Sm-HEDTMP的标记及小鼠体内分布研究  

Preparation and biodistribution of ^(153)Sm-HEDTMP

作　　者：蒋树斌[1] 罗顺忠[1] 胡疏[2] 邓候富[2] 邴文增[1] 王文进[1] 魏洪源[1] 雷勇[2] 

机构地区：[1]中国工程物理研究院核物理与化学研究所,绵阳621900 [2]四川大学华西医学中心附属第一医院核医学科,成都610041

出　　处：《核技术》2003年第5期388-392,共5页Nuclear Techniques

基　　金：国家自然科学基金(299771027)资助

摘　　要：制备了羟乙基乙二胺三甲撑膦酸(HEDTMP)的153Sm标记物,研究了标记物的标记条件、体外稳定性、化学计量组成、兔SPECT骨扫描及小鼠体内分布。结果表明,弱碱性介质、高配体量有助于标记物的形成,中性、弱碱性介质和高配体量有利于标记物的稳定,实验条件制备的标记物的化学计量组成为153SmHEDTMP=11,兔骨显像和小鼠体内分布表明标记物主要由动物骨骼系统摄取,是非常有希望的骨肿瘤缓解治疗剂。HEDTMP (N- (2- hydroxyethyl) ethlenediamine-1,1,2-tri(methylene phosphonic acid)) was synthesized and labeled with 153Sm. The labelling condition, stability, molar ratio of 153Sm to HEDTMP, rabbit bone imaging and biodistribution of 153Sm -EDTMP in mice were investigated. The results showed that weak basic media and high concentration ligand were favorable to form 153Sm-HEDTMP,and neutral or weak basic media increased stability of 153Sm-HEDTMP. The higher the concentration of HEDTMP, the more stable the labelled complex. The results also indicated that the chemical mole ratio of 153Sm-HEDTMP was 153Sm﹕HEDTMP=1﹕1 and the skeleton uptake of 153Sm-HEDTMP was high ((25.68 1.22)ID%/g bone at 3h and (16.56 1.01)ID%/g bone at 48h post-injection) while the nontarget tissue uptake is low. Therefore, 153Sm-HEDTMP may be a promising bone tumor therapeutic agent.

关 键 词：^153SM 经乙基乙二胺三甲撑膦酸 骨肿瘤 生物分布 

分 类 号：R979[医药卫生—药品] R817[医药卫生—药学]